Exclusive: Sanofi's strategy boss to leave as CEO readies revamp

This post was originally published on this site


PARIS (Reuters) – Sanofi’s (PA:) executive vice president in charge of strategy and business development, Muzammil Mansuri, a member of the French drugmaker’s executive committee, will leave the firm by the end of the month, according to a memo seen by Reuters.

The decision marks the first important management change taken since Paul Hudson became chief executive of Sanofi on Sept. 1, as he prepares to give pointers about his vision for the company next month.

Hudson and his teams are engaged in a strategic review and are expected to unveil the company’s priorities for the coming years at an investor day in Cambridge, Massachusetts in December.

Mansuri, who joined Sanofi in 2016 from Gilead Sciences (O:), will be retiring from the company, according to the document sent to staff on Wednesday.

Hudson said in the memo that Alban de la Sabliere, currently head of business development, and Laurent Van Lerberghe, head of strategy, would take on more responsibilities as of Dec. 1 and report directly to him.

A spokesman for Sanofi could not provide any immediate comment.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Add Comment